Key result
Stroke-associated pneumonia linked to ~3.2-fold higher risk of poor 90-day outcome.
Why the study?
Bacterial pneumonia aggravates ischemic stroke via mechanisms that remain to be determined, and stroke-associated pneumonia is linked to poor clinical outcomes and neutrophil deregulation.
Does stroke-associated pneumonia worsen clinical outcomes in patients with acute ischemic stroke?
Cohort (n=352)
No
Does stroke-associated pneumonia worsen clinical outcomes in patients with acute ischemic stroke?
Relative Risk: 3.2 (95% CI 1–9.9)
p-value: p=0.044
Stroke-associated pneumonia worsens 90-day clinical outcomes (RR 3.2) in patients, while this paper's preclinical experiments identify extracellular histones as drivers of this injury, reversible by histone neutralization.
Bacterial pneumonia aggravates ischemic stroke via mechanisms that still remain to be determined. In ischemic stroke patients, we show that stroke-associated pneumonia is associated with poor clinical outcome and long-term neutrophil deregulation. In mice exposed to transient middle cerebral artery occlusion (MCAO), experimental S. pneumoniae pneumonia induced at 3 days after stroke impaired neurological recovery and increased blood-brain barrier breakdown, brain neutrophil infiltrates, cerebral microvascular thrombosis, and progressive brain atrophy. The antibiotic amoxicillin only partially ameliorated pneumonia-associated neurological deficits and neutrophil infiltrates. Proteome analysis revealed that pneumonia induced a degranulation, platelet activation, and NETosis signature in peripheral blood neutrophils of MCAO mice, which was partly reversed by amoxicillin treatment. Subsequent studies showed that neutrophils were critical mediators of pneumonia-associated blood-brain barrier breakdown and microvascular thrombosis. Notably, administration of an antibody neutralizing extracellular histone proteins during pneumonia reduced ischemic injury, restored neurological recovery and prevented long-term brain atrophy in stroke-associated pneumonia mice. These protective effects were not observed after degradation of neutrophil extracellular traps by DNase-I, blockade of neutrophil extracellular trap formation by LDC7559 or myeloperoxidase inhibition by AZD4831, when these treatments were administered on occasion of pneumonia. This study identifies extracellular histones as key drivers of inflammatory brain injury and establishes histone neutralization as a strategy that protects against the deleterious effects of pneumonia after stroke.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) conducted a cohort in Acute ischemic stroke (n=352). Stroke-associated pneumonia vs. No stroke-associated pneumonia was evaluated on Poor stroke outcome at 90 days (RR 3.2, 95% CI 1.0-9.9, p=0.044). Stroke-associated pneumonia significantly increased the risk of poor clinical outcome at 90 days (RR 3.2) compared to patients without pneumonia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: